Valproate and palmitate binding to serum albumin in valproate-treated patients. relation to obesity
- 30 September 1993
- journal article
- research article
- Published by Elsevier in Epilepsy Research
- Vol. 16 (1) , 55-64
- https://doi.org/10.1016/0920-1211(93)90040-e
Abstract
No abstract availableKeywords
This publication has 28 references indexed in Scilit:
- Fatty acid and drug binding to a low‐affinity component of human serum albumin, purified by affinity chromatographyInternational Journal of Peptide and Protein Research, 1992
- Solubility of long-chain fatty acids in phosphate buffer at pH 7.4Biochimica et Biophysica Acta (BBA) - Lipids and Lipid Metabolism, 1992
- Binding of long‐chain fatty acids to serum albumin in healthy humans Relationship to obesityEuropean Journal of Biochemistry, 1991
- Valproate, Carnitine Metabolism, and Biochemical Indicators of Liver FunctionEpilepsia, 1990
- Serum albumin binding of palmitate and stearateEuropean Journal of Biochemistry, 1989
- Valproate: a new drug in migraine prophylaxisActa Neurologica Scandinavica, 1988
- Palmitate binding to serum albumin, measured by rate of dialysisEuropean Journal of Biochemistry, 1988
- Inhibition of gluconeogenesis by sodium valproate and its metabolites in isolated rat hepatocytesXenobiotica, 1985
- Effects of sodium valproate in 100 children with special reference to weight.BMJ, 1981
- The Interaction of Human Serum Albumin with Long-chain Fatty Acid AnionsJournal of the American Chemical Society, 1958